Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

A 58-year-old man comes to the cardiology clinic for a routine follow-up visit. He was diagnosed with ischemic cardiomyopathy and heart failure with reduced ejection fraction two years ago. Over the last two months, the patient reports increasing exertional dyspnea; he now becomes short of breath after walking up a single flight of stairs. His current medications include enalapril, carvedilol, spironolactone, and dapagliflozin. He is compliant with his medication regimen and a low-sodium diet. His blood pressure is 118/76 mmHg, and his heart rate is 68/min. Physical examination reveals clear lungs to auscultation bilaterally, no jugular venous distention, and trace bilateral pedal edema. Laboratory studies show a serum sodium of 138 mEq/L, potassium of 4.6 mEq/L, and creatinine of 1.2 mg/dL. The physician decides to replace the patient's angiotensin-converting enzyme (ACE) inhibitor with an angiotensin receptor-neprilysin inhibitor (ARNI) to further reduce morbidity and mortality. Which of the following is the most appropriate next step in modifying this patient's pharmacologic regimen?

  1. Discontinue enalapril, wait 36 hours, and then initiate sacubitril-valsartanCevap
  2. B
    Discontinue enalapril and immediately initiate sacubitril-valsartan at the next scheduled medication dose
  3. C
    Add sacubitril-valsartan to the current medication regimen without discontinuing any current medications
  4. D
    Discontinue spironolactone and enalapril, wait 36 hours, and then initiate sacubitril-valsartan
  5. E
    Discontinue carvedilol and enalapril, wait 36 hours, and then initiate sacubitril-valsartan

Cevap

Discontinue enalapril, wait 36 hours, and then initiate sacubitril-valsartan.
The correct intervention requires a 36-hour washout period between the discontinuation of an ACE inhibitor (enalapril) and the initiation of an ARNI (sacubitril-valsartan). Both ACE and neprilysin are enzymes responsible for the degradation of bradykinin. Administering an ARNI while an ACE inhibitor is still active in the patient's system leads to a profound, synergistic accumulation of bradykinin, which significantly increases the risk of life-threatening angioedema. The 36-hour timeframe allows for adequate clearance of the ACE inhibitor.

Adım Adım Çözüm

1
Evaluate the patient's current clinical status and indication for medication change.
The patient has worsening chronic HFrEF (NYHA Class III) despite optimal medical therapy including an ACE inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor.
Establishing the clinical indication confirms that upgrading from an ACE inhibitor to an ARNI (sacubitril-valsartan) is the correct guideline-directed step to reduce mortality.
2
Identify the pharmacokinetic and pharmacodynamic interactions involved in transitioning from an ACE inhibitor to an ARNI.
Both ACE inhibitors and neprilysin inhibitors (sacubitril) block the degradation of bradykinin. Overlapping active levels of both drugs cause synergistic bradykinin accumulation.
Understanding this interaction highlights the mechanism behind the severe risk of angioedema.
3
Apply the guideline-mandated transition protocol for this medication switch.
A strict 36-hour washout period is required after the last dose of an ACE inhibitor before the first dose of an ARNI can be safely administered.
This specific time frame allows the ACE inhibitor to clear sufficiently from the system, mitigating the risk of overlapping bradykinin inhibition and subsequent angioedema.

Anahtar Kavram

When transitioning a patient with heart failure from an ACE inhibitor to an ARNI, a 36-hour washout period is strictly required to prevent life-threatening angioedema due to overlapping inhibition of bradykinin degradation.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru